How Cellectar Biosciences, Inc. is positioning CLR 125 for a differentiated TNBC treatment thesis
Cellectar Biosciences, Inc. begins CLR 125 Phase 1b in refractory TNBC. Read what this could mean for precision radioconjugate oncology.
What Eric J. Daniels’ appointment means for Plus Therapeutics and its CNS oncology pipeline
Plus Therapeutics has named Eric J. Daniels as Chief Development Officer. Read what this means for REYOBIQ, CNS oncology execution, and pipeline risk.
Radiopharm Theranostics builds clinical momentum with RAD 101 data that could influence neuro-oncology workflows
Radiopharm Theranostics reports strong RAD 101 interim data in brain metastases imaging. Read expert analysis on clinical impact and regulatory outlook.
What TAG1’s Lead-212 supply deal with Dana-Farber reveals about the future of radiopharmaceutical oncology
TAG1 and Dana-Farber partner to expand Lead-212 access for targeted alpha therapies. Discover what this means for radiopharmaceutical oncology innovation.
Why BIOEMTECH and NorthStar Medical Radioisotopes’ Actinium-225 agreement matters for preclinical alpha therapy development
BIOEMTECH secures Actinium-225 supply from NorthStar. Find out why isotope access now defines radiopharmaceutical development timelines.
Aktis Oncology raises $318m IPO: What this means for alpha radiotherapy biotech bets
Can Aktis Oncology’s IPO jumpstart alpha radiopharma? Find out what its $318M raise means for solid tumor treatment and VC-to-IPO biotech strategy.
Curasight begins Phase 1 trial of uTREAT in glioblastoma, marking shift to clinical-stage radiopharma development
Curasight A/S has dosed the first patient in a Phase 1 clinical trial of uTREAT for glioblastoma, launching the therapeutic half of its uPAR-targeting theranostic platform alongside its companion diagnostic, uTRACE, which is already in Phase 2 for prostate cancer. How curative ambitions shift when a theranostic platform enters human testing in glioblastoma Curasight’s advancement […]